Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
market reach
Latest News
Janssen, Novartis up skin stakes
Competition: New data released in the battle for plaque psoriasis superiority.
TGA bill controversy not over
Legislation: Critics vow to contest regulations when they come to parliament.
PBAC becoming more opaque
Reputation: As number of meetings grows, transparency starts to slide.
D-day for pan-tumour drugs
Policy: PBAC convenes special meeting to consider listings across multiple tumour types.
Sanofi uncovers new fast track
Reimbursement: 12 months from TGA filing to listing for latest flu vaccine.
Most Popular
Pharmaco joins top employers
Workplace: Two pharmas join 13 companies with global Top Employer status but only one has it for Aust.
What GPs really want to know
Treatment Trends: Unique insight into treatment choices doctors feel least assured about.
BMS flags massive Plavix damages bill
Litigation: BMS has flagged the potential for close to $450m in damages plus interest needing to be paid should the Australian government succeed in its long-running case against over Plavix.
US pharma puts boot into Australia
Reputation: The US equivalent of MA, PhRMA, has filed a highly critical report on Australia with the office of the nation's most senior trade official calling for a 'watch' listing for our market.
World's best website? Ask GSK
Marketing: An annual ranking of corporate online excellence has seen the top two spots taken by pharma companies GSK and Bayer.
MSD cyber-attack was Russian
Security: Aust operations were collateral damage in cyber war on Ukraine.
Aust will wait for new CF combo
Market Access: TGA decision not expected till 2019 despite last week's US nod.
TGA provisional pathway now assured
Regulatory: Sansom review recommendation passes Senate.
Breast cancer PBS push wins support
Reimbursement: Patients win MP backing to list Kisqali, Ibrance.
Approvals Action
New delivery device for top biologic
TGA says Roche can market an updated method for injecting top-selling bDMARD.
Pipeline Monitor
Janssen nabs new prostate patient group
Janssen received a double win in prostate cancer this week after bagging US approval to extend Zytiga and market new drug Erleada, with the latter filed only four months ago.
Too early to think election? Think again
If you're not thinking about the PBS in an election context, then think again. With a federal election looming, the government is already viewing spending through its pre-election lens.
FREE Content
Events & Conferences
Pharma in Focus Jobs